Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic efficacy of palivizumab against RSV in healthy adults
2020-001044-26Phase 2Unknown
- Sponsor
- mAbxience
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Palivizumab (Synagis) with Placebo (2 arms). Status: unknown.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-001044-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001044-26.